| Registro completo |
| Provedor de dados: |
BJID
|
| País: |
Brazil
|
| Título: |
Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
|
| Autores: |
Parise,E.
Cheinquer,H.
Crespo,D.
Meirelles,A.
Martinelli,A.
Sette,H.
Gallizi,J.
Silva,R.
Lacet,C.
Correa,E.
Cotrim,H.
Fonseca,J.
Paraná,R.
Spinelli,V.
Amorim,W.
Tatsch,F.
Pessoa,M.
|
| Data: |
2006-02-01
|
| Ano: |
2006
|
| Palavras-chave: |
Peginterferon alfa
Ribavirin
Hepatitis C
Safety
Efficacy
|
| Resumo: |
Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous nonresponder US patients. We evaluated the effectiveness of peginterferon alfa-2a (40KD) plus ribavirin in Brazilian patients who were relapsers or nonresponders to previous interferon-based therapy. One-hundred-thirty-four patients with biopsy-proven chronic hepatitis C, HCV RNA positive, elevated ALT and who were either relapsers (n=37) or nonresponders (n=97) to at least 24 weeks of conventional interferon/ribavirin therapy were retreated with peginterferon alfa-2a (40KD) 180mg/qw and ribavirin 800mg bid for 48 weeks. Efficacy was assessed as virological response (defined as undetectable HCV RNA) at the end of treatment (EoT) and at the end of follow-up (SVR - Sustained Virological Response). Safety assessments consisted of clinical and laboratory evaluations. In the patient sample, 72% were genotype 1 and 34% were cirrhotic. In an intention-to-treat analysis, relapser patients showed 78% EoT response and 51% SVR. Nonresponders showed 57% EoT response and 26% SVR. Positive predictive factors of SVR were non-1 genotype and relapser state. Six percent of the patients interrupted treatment because of adverse events and 45% had dose reduction (mainly associated with leucopenia and anemia). Brazilian patient relapsers and nonresponders to conventional interferon and ribavirin treatment can achieve a sustained virological response when retreated with peginterferon alfa-2a (40KD) and ribavirin. The safety profile is similar to that of naive patients.
|
| Tipo: |
Info:eu-repo/semantics/article
|
| Idioma: |
Inglês
|
| Identificador: |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000100003
|
| Editor: |
Brazilian Society of Infectious Diseases
|
| Relação: |
10.1590/S1413-86702006000100003
|
| Formato: |
text/html
|
| Fonte: |
Brazilian Journal of Infectious Diseases v.10 n.1 2006
|
| Direitos: |
info:eu-repo/semantics/openAccess
|
|
